The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Performance was driven by a strategy of leveraging unique technologies for custom-engineered solutions at scale for blue-chip customers in high-growth markets.

The Precision Devices segment saw broad-based 17% growth across medtech, defense, industrial, and electrification, supported by a sixth consecutive quarter with a book-to-bill ratio above 1.0.

Defense market strength is attributed to ongoing OEM programs, new production starts, and share gains, with additional demand expected from global stock replenishment.

Industrial growth was supported by ceramic capacitor demand in semiconductor equipment and downhole applications, following the resolution of prior-year inventory challenges.

MedTech and Specialty Audio growth of 14% was fueled by successful new product introductions from customers, though management expects this to normalize to historical rates for the full year.

Management attributes premium margins to the company's ability to solve complex engineering problems and ramp production quickly for demanding applications.

Full-year 2026 revenue growth is now expected to exceed the high end of the original 4% to 6% organic target range due to a robust order backlog.

Adjusted EBITDA growth for 2026 is projected to surpass the cumulative annual growth target of 10% to 14% based on strong momentum through the first four months.

Precision Devices gross margins are expected to expand in the second half of 2026 as the specialty film production line for a major energy order fully ramps and yields improve.

Defense demand is anticipated to strengthen further in 2027, with the level of activity relative to global events remaining very high.

The company plans to increase content per device in next-generation hearing health products, providing a future opportunity to exceed historical growth rates in the MedTech segment.

A $75 million-plus energy order is currently in a production ramp-up phase, which created temporary factory cost headwinds in the specialty film line during Q1.

Cash flow from operations included $8 million in outflows related to the CMM business divested in 2024, with these payments now considered substantially complete.

Management noted that while transportation costs are low, they are monitoring modest increases in resin-based input costs, though these are not currently significant to the bill of materials.

The company maintains a low net leverage ratio of 0.6 times, providing over $310 million in liquidity for strategic flexibility.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management expects to achieve annual price increases in the 2% to 4% range for the Precision Devices segment by targeting specific markets and products where they hold strong positions.

Gross margins in Precision Devices are projected to improve by approximately 100 basis points for the full year, driven by a 200 to 250 basis point improvement in the second half as the energy order ramps.

There is an increasing trend of defense customers seeking long-term agreements spanning three to five years, a shift from the typical one-year order cycle.

The current 1.19 book-to-bill ratio is considered high-quality, with approximately 97% of those orders scheduled to ship within the next twelve months.

Knowles is focusing on high-performance, specialized RF filters for the satellite market rather than commoditized, low-cost components.

The RF group saw double-digit growth in Q1, contributing significantly to the overall Precision Devices segment performance.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.